Nasdaq
$9.21▲ 0.71%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.13BShares out 3.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 4d agoPre-market26.10.21 08:40filed6-KKey event#●●●#●●●#●●●
Telix Pharmaceuticals LtdBullish
Telix Pharmaceuticals reported Q3 2026 revenue of $245 million, representing a 19% increase year-over-year. The company announced a $1.65 billion merger with Isotope Technologies Munich SE (ITM) to expand its radiopharmaceutical platform and reaffirmed its FY 2026 revenue guidance of over $1 billion.…more
$9.21+0.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30Pre-market26.09.30 09:19filed6-KKey event
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals has been granted FDA Fast Track designation for its BiPASS program, which evaluates prostate cancer imaging prior to biopsy. This designation facilitates more frequent engagement with the FDA and may expedite the review process for the company's planned New Drug Application (NDA).…more
$9.21+0.71%vs prev closeView filingShare - 9.21Pre-market26.09.21 21:556-KKey event
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals has entered into a strategic agreement to acquire ITM Isotope Technologies Munich SE for US$1.65 billion. This merger enables Telix to vertically integrate its operations by securing ITM's radioisotope supply chain and its late-stage therapeutic pipeline, including the Phase 3-completed ITM-11. The transaction, consisting of US$1.25 billion in Telix shares and debt assumption, is expected to close by the end of FY 2026.…more
$9.21+0.71%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoOvernight26.10.21 16:41Bullish#●●●#●●●
Telix Reports Q3 Revenue of $245M, Up 19% YoY
Telix reported a Q3 revenue of $245 million, marking a 19% increase year-over-year. The growth was driven by a 30% rise in precision medicine revenue, fueled by strong demand for Gozellix and Illuccix.…more
$9.21+0.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoAfter-hours26.10.21 07:10
●●●●●●●● ●●●●● ●●●●●●
Telix posted a 19% year-over-year revenue increase in Q3, driven by strong demand for its commercial portfolio, and reaffirmed its full-year revenue outlook exceeding $1 billion. The company is also advancing its strategic growth through a planned merger with ITM to expand its radiopharmaceutical capabilities.…more
$9.21+0.71%vs prev close - 6d agoOvernight26.10.19 14:30
●●●●●●●● ●●●●● ●●●●●●
Telix Pharmaceuticals is collaborating with Ekalia to establish a dedicated U.S. production framework for astatine-211, a next-generation isotope for targeted alpha therapy. This partnership aims to secure a long-term supply chain for Telix's clinical pipeline and broader research programs.…more
$9.21+0.71%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report